Date: 2017-07-11
Type of information: Nomination
Compound:
Company: Poxel (France)
Therapeutic area: Metabolic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On July 11, 2017, Poxel announced the addition of Kumi Sato, President and CEO of COSMO Public Relations Corporation, to its Board of Directors. Ms. Sato is a seasoned executive with over 30 years’ experience advising companies in business and communication strategy, with a particular focus on Japanese business strategies for healthcare companies. The appointment was approved by Poxel’s shareholders at the Annual Shareholder Meeting, which was held in Paris on Friday, June 30, 2017.
- “Following the announcement last quarter that the Imeglimin Phase 2b trial in Japan successfully met its primary and secondary endpoints and given that preparation for the Phase 3 program is well under way, Kumi’s appointment as our first Japanese board member comes at a very important time for Poxel,” said Thomas Kuhn, CEO of Poxel. “Japan is a key area of focus and an integral part of our business strategy. Her expertise and insights into the Japanese healthcare market will be invaluable as we continue to advance Imeglimin’s development.”
- For over 30 years, Kumi Sato has served as President and CEO of Cosmo Public Relations Corporation, an award-winning strategic communications and public affairs firm based in Tokyo, Japan, with a specialized healthcare division, COSMO Healthcare. In 2010, she founded BioCube, a think-tank to discuss Japan’s healthcare system and biotech-related topics. She currently serves as an advisor to the Global Health Innovative Technology Fund in Tokyo, a lecturer at the Graduate School of Business Breakthrough University and is Chairman Emeritus of the American Chamber of Commerce in Japan.
Financial terms:
Latest news:
Is general: Yes
